Pharmacovigilance Obligations. After the Closing, Seller shall promptly provide Purchaser an electronic copy of the CIOMS I form for all legacy data of Adverse Events with respect to any Seller Product that is within Seller’s (or its Affiliate’s, as appropriate) possession, for inclusion in Purchaser’s safety database for the Product. After the Closing, Purchaser shall have all responsibility for required reporting of Adverse Events with respect to Seller Products.
Appears in 4 contracts
Samples: Asset Purchase Agreement (Pernix Therapeutics Holdings, Inc.), Asset Purchase Agreement (Zogenix, Inc.), Asset Purchase Agreement (Pernix Therapeutics Holdings, Inc.)
Pharmacovigilance Obligations. After the Closing, subject to the Transition Services Agreement, the Seller Parties shall promptly provide Purchaser an electronic copy of the CIOMS I form for all legacy data of Adverse Events recorded prior to the Closing with respect to any Seller Product that is within Seller’s the Seller Parties’ (or its their Affiliate’s, as appropriate) possession, for inclusion in Purchaser’s safety database for the Seller Product. After the Closing, Purchaser shall have all responsibility for required reporting of Adverse Events with respect to Seller ProductsProducts in the Territory.
Appears in 1 contract
Samples: Asset Purchase Agreement (Apricus Biosciences, Inc.)
